Intraocular pressure changes following intravitreal anti-VEGF injections in AMD patients
DOI:
https://doi.org/10.63682/jns.v14i17S.4605Keywords:
age-related macular degeneration, Bevacizumab, ranibizumabAbstract
age-related macular degeneration (AMD) as well as other eye disorders linked to choroidal neovascularisation (CNV). The present study was assessed intraocular pressure changes following intravitreal anti-VEGF injections in AMD patients.
Materials & Methods: 45 wet age-related macular degeneration (AMD) patients of both genderswere divided into 3 groups of 15 each. Group I patients received bevacizumab (1.25 mg/0.05 ml), group II patients received ranibizumab (0.5 mg/ 0.05 ml)and group III patients received both bevacizumab (1.25 mg/0.05 ml), and ranibizumab (0.5 mg/ 0.05 ml). Parameters such as prevalence of intraocular pressure elevations and mean interval between injections (days) were recorded.
Results: There were 15 patients and 30 eyes in all groups. The mean age was 68.4 years, 70.2 years and 74.2 years and pre-existing glaucoma was seen in 4, 3 and 1 patient in group I, II and III respectively. The difference was significant (P< 0.05). In pre-existing glaucoma, IOP elevations was seen in 3, in group I in 2, in group II in 2 and in group III in 0 patients. The mean interval between injections was 65.2 days, 87.5 days, 54.2 days and 50.4 days respectively. The difference was significant (P< 0.05).
Conclusion: The occurrence of sustained elevated IOP in patients receiving intravitreal anti-VEGF injections is considerable. Moreover, these data indicate that patients with pre-existing glaucoma who are treated with either bevacizumab or ranibizumab may have an increased risk of further IOP elevation.
Downloads
References
Jeong S, Sagong M, Chang W. Acute angle closure attack after an intravitreal bevacizumab injection for branch retinal vein occlusion: a case report. BMC Ophthalmol. 2017;17:25.
Kim IK, Baek J. A case of refractory acute angle closure glaucoma after an intravitreal bevacizumab injection. Korean J Ophthalmol. 2020;34:493–494.
Alkin Z, Perente I, Altan C, et al. Changes in anterior segment morphology after intravitreal injection of bevacizumab and bevacizumab–triamcinolone acetate combination. Eur J Ophthalmol. 2013;23:504–509.
Entezari M, Ramezani A, Yaseri M. Changes in retinal nerve fiber layer thickness after two intravitreal bevacizumab injections for wet type age-related macular degeneration. J Ophthalmic Vis Res. 2014;9:449–452.
Horsley MB, Mandava N, Maycotte MA, et al. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010;150:558.e1–561.
Jo Y-J, Kim W-J, Shin I-H, et al. Longitudinal changes in retinal nerve fiber layer thickness after intravitreal anti-vascular endothelial growth factor therapy. Korean J Ophthalmol. 2016;30:114–120.
Parlak M, Oner FH, Saatci AO. The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration. Int Ophthalmol. 2015;35:473–480.
Soheilian M, Karimi S, Montahae T, et al. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study. Graefes Arch Clin Exp Ophthalmol. 2017;255:1705–1712.
Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. British Journal of Ophthalmology. 2011 Aug 1;95(8):1111-4.
Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009;40:293–295.
de Vries VA, Bassil FL, Ramdas WD. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep. 2020;10:13248.
Cui QN, Gray IN, Yu Y, et al. Repeated intravitreal injections of anti-vascular endothelial growth factors and risk of intraocular pressure medication use. Graefes Arch Clin Exp Ophthalmol. 2019;257:1931–1939.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
